Which combination is appropriate for the treatment of moderate asthma?

Which combination is appropriate for the treatment of moderate asthma?

• A. Low dose ICS + LABA
• B. High dose ICS + SABA
• C. Leukotriene receptor antagonist + SABA
• D. Just SABA alone

Answer: (A)

For the treatment of moderate asthma, the recommended approach involves the use of a low dose inhaled corticosteroid (ICS) in combination with a long-acting beta-agonist (LABA). This combination is effective because the ICS targets the underlying inflammation associated with asthma, helping to reduce bronchial hyper-responsiveness and decrease the frequency of asthma attacks. The LABA complements this by providing bronchodilation, enhancing airflow and improving overall control of symptoms. In moderate asthma, using just a short-acting beta-agonist (SABA) alone, or even just a leukotriene receptor antagonist, would not provide sufficient control of symptoms and does not address the inflammatory component adequately. High dose ICS with a SABA may also be over-treatment in the context of moderate asthma, and should typically be reserved for more severe cases. Therefore, the combination of a low dose ICS and LABA represents an effective, evidence-based strategy for managing moderate asthma.

For the treatment of moderate asthma, the recommended approach involves the use of a low dose inhaled corticosteroid (ICS) in combination with a long-acting beta-agonist (LABA). This combination is effective because the ICS targets the underlying inflammation associated with asthma, helping to reduce bronchial hyper-responsiveness and decrease the frequency of asthma attacks. The LABA complements this by providing bronchodilation, enhancing airflow and improving overall control of symptoms.

In moderate asthma, using just a short-acting beta-agonist (SABA) alone, or even just a leukotriene receptor antagonist, would not provide sufficient control of symptoms and does not address the inflammatory component adequately. High dose ICS with a SABA may also be over-treatment in the context of moderate asthma, and should typically be reserved for more severe cases. Therefore, the combination of a low dose ICS and LABA represents an effective, evidence-based strategy for managing moderate asthma.